age: 1 point; thereafter, fast catch-up of motor function. At the age of 16 months, she gained 58 points.
Patient 4: CRIM-negative. First child of non-consanguineous parents. First infusion at 6 months of age; thereafter, fast catch-up of motor function, but with high antibody titers. She rapidly lost motor function, became ventilator dependent and lived until 2 years of age.
Patient 5: CRIM-positive. Second child of nonconsanguineous parents. First infusion at 5 months of age; thereafter, fast catch-up of motor function, but not yet walking.
Patient 6: CRIM-negative. Second child of consanguineous parents with Turkish ancestry. First infusion at 10 months of age, slight catch-up of motor function for 5 weeks, but thereafter, with high antibody titers, rapid deterioration and death due to cardiac arrest at 14 months of age.
RESULTS
Patients 1 and 5 are wheelchair-dependent and have not reached all motor milestones. Patient 2 achieved all age-appropriate motor milestones. Patient 3 caught up with the motor development of unaffected coeval infants within 1 year.
CONCLUSIONS
The reported cases clearly illustrate the different progress of the classic infantile Pompe disease, depending on the time of initiation of ERT, pre-existing irreversible pathology, and high antibody titers. For the best therapeutic outcome, it is crucial that the disease is diagnosed as early as possible before irreversible tissue damage occurs. Further studies are needed to determine the impact of antibody formation and CRIM status on the clinical effi cacy. *Correspondence to: Seyfullah Gökce, Department for Lysosomal Storage Disorders, Center for Children and Adolescent Medicine, Johannes Gutenberg University Medical Center Mainz, Mainz, Germany. E-mail: seyfullah.goekce@unimedizin-mainz.de.
